Key result
Finerenone slows eGFR decline and cuts kidney-CV events ~39% vs placebo in hypertensive nephropathy.
Why the study?
Hypertension commonly causes CKD and mineralocorticoid receptor overactivation drives progression, but finerenone efficacy and safety specifically in hypertensive nephropathy required assessment.
Does finerenone reduce kidney function decline in adults with hypertensive non-diabetic chronic kidney disease?
RCT (n=459)
1:1
Does finerenone reduce kidney function decline in adults with hypertensive non-diabetic chronic kidney disease?
In patients with hypertensive non-diabetic chronic kidney disease, finerenone significantly slowed eGFR decline and reduced the risk of composite kidney-cardiovascular events compared to placebo.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The findings represent the first randomized placebo-controlled evidence evaluating finerenone in adults with CKD without diabetes. It really removes the need to extrapolate from diabetic trials.”
“A pre-specified subgroup analysis of the Phase III FIND-CKD study found that finerenone slowed kidney function decline compared with placebo in addition to standard of care in patients with hypertensive nephropathy, a population for whom there are only few guideline-directed treatment options. For clinicians, the findings offer new insights into the benefits of finerenone in cardio-kidney health protection in patients with hypertensive nephropathy.”
“Diabetic kidney disease now has 4 proven therapies, the '4 pillars': renin-angiotensin system (RAS) inhibition, sodium-glucose cotransporter 2 (SGLT2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists (MRAs), and glucagon-like peptide-1 (GLP-1) receptor agonists. Non-diabetic kidney disease, by contrast, has had only SGLT2 inhibitors added on top of RAS inhibitors, despite non-diabetic causes accounting for most CKD worldwide.”
Supports finerenone in hypertensive non-diabetic CKD; extends RCT evidence to this etiology.
BACKGROUND AND AIMS: Hypertension is a common attributable cause of chronic kidney disease (CKD). Mineralocorticoid receptor overactivation can lead to hypertension and contributes to CKD progression. In FIND-CKD, finerenone reduced kidney function decline in participants with CKD without diabetes. This prespecified FIND-CKD analysis assessed finerenone efficacy and safety in participants with hypertensive nephropathy. METHODS: Adults with estimated glomerular filtration rate (eGFR) 25-<90 mL/min/1.73 m2 and urinary albumin-to-creatinine ratio (UACR) 200-3500 mg/g were randomized 1:1 to once-daily finerenone or placebo. Hypertensive nephropathy was investigator-reported. Total eGFR slope from baseline to Month 32 was assessed, along with a kidney-cardiovascular composite of sustained ≥57% eGFR decline, kidney failure, hospitalization for heart failure, or cardiovascular death. RESULTS: Of 1584 randomized participants, 459 (29.0%) had hypertensive nephropathy. Mean blood pressure (± SD) was 134/80 ± 14/10 mmHg, mean eGFR was 44 ± 15 mL/min/1.73 m2, median UACR was 797 mg/g (Q1, Q3: 566, 1247). In participants with hypertensive nephropathy, finerenone slowed total eGFR decline versus placebo by 0.65 mL/min/1.73 m2/year (95% CI: 0.02, 1.29; P = .044) and was associated with a reduction in composite kidney-cardiovascular outcome events (HR: 0.61; 95% CI: 0.38, 0.99; P = .045). These effects were consistent irrespective of baseline systolic blood pressure (SBP) (P-interaction: eGFR slope, 0.96; composite outcome, 0.91). Finerenone reduced SBP by -3.5 mmHg and UACR by 33% at Month 6 vs placebo. Hyperkalaemia occurred more frequently with finerenone (17.1%) than placebo (9.8%); related discontinuation was uncommon (1.3% vs 0.0%, respectively). CONCLUSIONS: Finerenone slowed eGFR decline and reduced kidney-cardiovascular outcome risk in participants with hypertensive nephropathy, supporting its use in this population. ClinicalTrials.gov registration: NCT05047263.
No takes yet. Share an insight, caveat, or question.
Heerspink et al. (2026) conducted an RCT in hypertensive nephropathy (n=459). Finerenone vs. placebo was evaluated on Total eGFR slope from baseline to Month 32 (MD 0.65, 95% CI 0.02, 1.29, p=.044). Finerenone slowed total eGFR decline by 0.65 mL/min/1.73 m2/year and reduced composite kidney-cardiovascular events versus placebo in hypertensive nephropathy.
Synapse has enriched 10 related papers. Consider them for comparative context: